Alternative Treatments for Premenstrual Dysphoric Disorder

• ClinicalTrials.gov Identifier: NCT01799733
• Recruitment Status: Unknown
• First Posted: February 27, 2013
• Last Update Posted: January 11, 2018
• Sponsor: University of California, San Diego
• Information provided by (Responsible Party): Barbara L. Parry, M.D., University of California, San Diego

Study Description

Brief Summary:

The primary aim of this study is to examine the effects of co-administered wake therapy followed by light treatment on mood, and secondarily on circadian rhythms, to test the hypothesis that critically-timed chronotherapy improves mood by correcting phase disturbances in melatonin and sleep in women with Premenstrual Dysphoric Disorder.

Condition or disease	Intervention/treatment	Phase
Premenstrual Dysphoric Disorder	Other: LWT+AM BWL; Other: EWT+PM BWL	Not Applicable

Detailed Description:

The design is a randomized cross-over contrasting Late Wake Therapy plus morning bright light (LWT+Am BWL)vs. Early Wake Therapy plus evening bright light (EWT+PM BWL)administered in the luteal phase of two separate menstrual cycles, and preceded by 2 evaluation months. To lessen the patient's burden, the 1-night EWT or LWT and the following 7-day BWL interventions will be conducted at home, given at a fixed point in each menstrual cycle, from day 1 to 7 after the mid-cycle luteinizing hormone(LH) surge (ovulation). We anticipate that LWT+7 days of AM BWL (vs. EWT+PM BWL) will produce much greater mood benefits and larger physiological responses, than the one-time light pulses used in our earlier phase-shift studies.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Single (Investigator)
• Primary Purpose: Treatment
• Official Title: Alternative Treatments for Premenstrual Dysphoric Disorder
• Study Start Date: June 2013
• Estimated Primary Completion Date: June 2018
• Estimated Study Completion Date: June 2018

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: LWT+AM BWL; Late-wake therapy in combination with morning bright white light	Other: LWT+AM BWL; One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
Placebo Comparator: EWT+PM BWL; Early-wake therapy in combination with evening bright white light	Other: EWT+PM BWL; One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)

Outcome Measures

Primary Outcome Measures :

1. Treatment-Related Changes from baseline in mood ratings [ Time Frame: baseline (month 2) and 1-2 days post intervention (months 3,5) ]
   Mood ratings include Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory (BDI), atypical depression symptoms as part of the Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders version (SIGH-SAD), Beck Anxiety Inventory (BAI), mania ratings, the Psychological General Well-Being Index (PGWI) and daily mood self-ratings (DMR) that include core PMDD symptoms of anxiety and irritability as required during diagnostic evaluation, before, during and after each wake and light intervention at the same time of day (between 15:00-17:00 h). To assess more acute effects on mood that may occur more rapidly during the wake interventions, subjects will complete DMRs twice daily beginning the evening before the wake therapy intervention and continuing until the morning after the recovery night of sleep.
2. Treatment-Related Changes from Baseline in Urinary 6-sulfatoxymelatonin (6-SMT) [ Time Frame: baseline (month 2) and 1-2 days post intervention (months 3,5) ]
   6-SMT is a principal melatonin metabolite that is abundant in urine, well correlated with plasma melatonin, and serves as an excellent marker for circadian phase response.
3. Treatment-related changes in objective and subjective sleep measures [ Time Frame: baseline (month 2) and 1-2 days post intervention (months 3,5) ]
   Using actigraphy, we will obtain objective measures of the sleep/wake cycle to ensure appropriate sleep/wake times during wake therapy, and during the light interventions as it is an important biological rhythm with which to compare the intervention-induced melatonin rhythm changes. To assess subjective sleep quality, we will use the Pittsburgh Sleep Quality Index (PSQI) and a visual analogue scale.

Secondary Outcome Measures :

1. Effects of expectation, morningness/eveningness and seasonality on primary outcome measures [ Time Frame: baseline ]
   Prior to entering the study, subjects will complete expectation forms measuring their expectation for change with the interventions (100 mm line from "much worse" to "much better") as well as Horne-Östberg scales to assess morningness and eveningness, as these variables may mediate or moderate primary outcome measures. To determine whether seasonality affects outcome, subjects will complete the Seasonal Pattern Assessment Questionnaire (SPAQ).
2. Treatment-related changes from baseline in reproductive hormones [ Time Frame: baseline (month 2) and 1-2 days post intervention (months 3,5) ]
   We will obtain overnight urinary samples for estradiol, progesterone, gonadotropins and prolactin (obtained at the same time of 6-SMT overnight collections in baseline and intervention months).
3. Subjective visual analog scale-based global assessment of treatment effectiveness [ Time Frame: 1-2 days post second intervention (month 5) ]
   Following both treatment interventions, subjects will complete a visual analog scale-based global assessment of treatment effectiveness.
4. Subjective assessment of side effects to treatment [ Time Frame: 1-2 days post intervention (months 3,5) ]
   Following each treatment interventions, subjects will complete an assessment of side effects using the Side Effects Checklist.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 45 Years (Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age: 18-45 years.
• Women with regular ovulatory menstrual cycles 26-32 days in length (for at least the previous six months).
• A history of a depressive (but not bipolar) mood disorder, but not an ongoing episode (symptom free for the last 12 months).
• Patients must meet DSM-IV criteria for Premenstrual Dysphoric Disorder (that includes irritability).
• Objective ratings: mean HRSD < 7 for follicular phase (day 5-10 of cycle after menses); mean HRSD > 14 for premenstrual (luteal) phase (6 days prior to onset of menses onward).
• Subjective ratings: mean Beck Depression Inventory < 5 follicular phase; > 10 premenstrual (luteal) phase, or
• Daily ratings: minimal symptoms (mean less than 50 on 100mm scale) follicular phase; at least a 30% increase in mean affective symptom ratings, premenstrual (luteal) phase.
• By clinical assessment and ratings, the patient has reported a history (for at least the last six months) of recurrent, moderate to severe premenstrual mood symptoms that impair some aspect of social or occupational functioning and that remit within a few days after the onset of menses. This pattern is prospectively documented with subjective and objective ratings over a 2-3 month interval. Patients must demonstrate a consistency of symptoms and a long enough duration of symptoms (7-10 days) to allow for study.
• Subjects willing to endure the rigors of a long-term (up to 6 months) research study.

Exclusion Criteria:

• Subjects with significant medical illness including hepatic (abnormal liver function tests), neurological, renal, cardiac, pulmonary, hematologic, gastrointestinal, or metabolic disorders.
• Subjects who are lactating, are within 6 months postpartum, or have an irregular sleep- wake cycle, e.g., from having very young children in the home.
• Subjects who are using hormonal contraception (within six months prior to the study).
• Subjects using other medication within one month of initiating the study or anytime during the study.
• Subjects with significant psychiatric disorder (schizophrenia, bipolar disorder, anxiety disorders, eating disorders, personality disorders, sleep disorders). An ongoing major depressive episode within the last year is reason for exclusion, although a previous history of a depressive episode is not (using DSM-IV diagnostic criteria for a major depressive episode).
• Subjects with a recent history (within the past year) of drug or alcohol abuse.
• Subjects with clinically significant abnormal laboratory values.
• Subjects with irregular menstrual cycles (cycle lengths vary greater than 3 days).
• Subjects unlikely to cooperate with the requirements of the study.
• Subjects needing frequent or continuous use of any medication, including nicotine (> 5 cigarettes daily).
• Subjects whose prospective ratings do not show cyclic variation in association with the menstrual cycle (as per inclusion criteria).
• Subjects with an irregular sleep schedule, extreme chronotypes or a sleep-wake cycle that does not correspond to the environmental light-dark cycle (e.g., subjects within 2 weeks of transmeridian travel, night shift workers, or those with significant advanced or delayed sleep phase syndromes). To enhance precision of the timing of the light stimulus on circadian phase (temporal resolution), we will exclude women with habitual sleep onset times after midnight or wake times after 9 am.

Contacts and Locations

Contacts

Contact: Diane L Sorenson, MPH; 619-543-5575; dsorenson@ucsd.edu

Contact: Luis F Martinez, B.A.; 619-543-7917; lfmartinez@ucsd.edu

Locations

United States, California

UCSD Medical Center, Hillcrest; Recruiting

San Diego, California, United States, 92103

Contact: Diane L Sorenson, MPH 619-543-5575 dsorenson@ucsd.edu

Contact: Luis F Martinez, B.A. 619-507-1182 lfmartinez@ucsd.edu

Principal Investigator: Barbara L Parry, M.D.

Sub-Investigator: Charles J Meliska, Ph.D.

Sub-Investigator: Richard Hauger, M.D.

Sub-Investigator: Shah Golshan, Ph.D.

Sponsors and Collaborators

University of California, San Diego

Investigators

• Principal Investigator: Barbara L Parry, M.D.; University of California, San Diego

More Information

• Responsible Party: Barbara L. Parry, M.D., Professor IR, University of California, San Diego
• ClinicalTrials.gov Identifier: NCT01799733
• Other Study ID Numbers: 1R01AT007169-01A1 ( U.S. NIH Grant/Contract )
• First Posted: February 27, 2013
• Last Update Posted: January 11, 2018
• Last Verified: January 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Barbara L. Parry, M.D., University of California, San Diego:

Premenstrual Dysphoric Disorder; Women; Depression; Light therapy; Wake therapy; Phase; Chronobiology

Additional relevant MeSH terms:

Disease; Premenstrual Dysphoric Disorder; Pathologic Processes; Premenstrual Syndrome; Menstruation Disturbances; Depressive Disorder; Mood Disorders; Mental Disorders